According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
68
Ciclesonide 320ug oral inhalation q12h for 14 days
Korea University Guro Hospital
Seoul, South Korea
Rate of SARS-CoV-2 eradication at day 14 from study enrollment
Viral load
Time frame: Hospital day 14
Rate of SARS-CoV-2 eradication at day 7 from study enrollment
Viral load
Time frame: Hospital day 7
Time to SARS-CoV-2 eradication (days)
Viral load
Time frame: Hospital day 1, 4, 7, 10, 14, 21
Viral load area-under-the-curve (AUC) reduction versus control
Viral load change
Time frame: Hospital day 1, 4, 7, 10, 14, 21
Time to clinical improvement (days)
Resolution of all systemic and respiratory symptoms for ≥2 consecutive days
Time frame: Up to 28 days
Proportion of clinical failure
High-flow oxygen therapy or mechanical ventilation requiring salvage therapy
Time frame: Up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.